{
      "ptx_code": "PTX141",
      "chem_name": "Naproxen",
      "casrn": "22204-53-1",
      "dtxsid": "DTXSID4040686",
      "smiles": "COC1=CC2=CC=C(C=C2C=C1)[C@H](C)C(O)=O",
      "inchikey": "CMWTZPSULFXXJA-VIFPVBQESA-N",
      "label": "PTX141 | Naproxen",
      "drugbank_id": "DB00788",
      "use_class": "Pharmaceutical",
      "tox_class": "Nephrotoxicity; Neurotoxicity; Hepatotoxicity; Immunotoxicity; Cardiotoxicity; Genotoxicity",
      "chem_name_user": "Naproxen",
      "mw_g_mol": "230.263",
      "solubility_h2o_mol_liter": "5.81763e-05",
      "source_solubility_h2o": "COMPTOX (OPERA)",
      "henry_coefficient_atm_m3_mol": "1.0624e-09",
      "source_henry": "COMPTOX",
      "log_kaw_kh_rt": "7.36202160980878",
      "source_kaw": "LSER eq 1 exp. Descriptors",
      "pka_acid": "4.19",
      "pka_base": "",
      "source_pka": "UFZ; Sirius T3",
      "log_kow_liter_liter": "3.18",
      "source_kow": "PhysPropNCCT (COMPTOX)",
      "log_dlipw_ph74_liter_liter": "2.17",
      "source_dlipw": "Henneberger et al. 2019",
      "freely_dissolved_fraction": "0.00205105745326953",
      "density_kg_liter": "1.212",
      "source_density": "COMPTOX",
      "baseline_drerio": "1180.0",
      "baseline_dmagna": "559.0",
      "baseline_celegans": "1217.98955607273",
      "baseline_xlaevis": "363.763399621965",
      "baseline_dmelanogaster": "4921.92509447592",
      "baseline_cells": "0.0857029008727705",
      "baseline_cells_generic_micromole_liter_free_ec10": "0.000175781573601915",
      "moa_drugbank": "As with other non-selective NSAIDs, naproxen exerts it's clinical effects by blocking COX-1 and COX-2 enzymes leading to decreased prostaglandin synthesis.[A178975] Although both enzymes contribute to prostaglandin production, they have unique functional differences.[A178975] The COX-1 enzymes is constitutively active and can be found in normal tissues such as the stomach lining, while the COX-2 enzyme is inducible and produces prostaglandins that mediate pain, fever and inflammation.[A178990] The COX-2 enzyme mediates the desired antipyretic, analgesic and anti-inflammatory properties offered by Naproxen, while undesired adverse effects such as gastrointestinal upset and renal toxicities are linked to the COX-1 enzyme.[A178990]",
      "protein_binding": "Naproxen is highly protein bound with >99% of the drug bound to albumin at therapeutic levels.[L6582][L6583]",
      "moa_t3db": "",
      "aop": [
            {
                  "AOP_id": 6,
                  "AOP_name": "Antagonist binding to PPAR\u03b1 leading to body-weight loss "
            },
            {
                  "AOP_id": 72,
                  "AOP_name": "Epigenetic modification of PPARG leading to adipogenesis "
            }
      ],
      "targets": []
}